Here's the Deal
Baird's Investment Banking Group is pleased to announce the following transaction:
A Portfolio Company of Cortec Group Sale to Linsalata Capital Partners
Baird served as the exclusive financial advisor to NeuroTherm on this transaction
RF Medical Holdings, Inc. (“NeuroTherm” or the “Company”), a portfolio company of Cortec Group Fund III, L.P., an affiliate of Cortec Group (“Cortec”), recently completed its sale to Linsalata Capital Partners (“Linsalata”). Terms of the transaction were not disclosed.
NeuroTherm is a leading developer, manufacturer and provider of products and services in the rapidly growing interventional pain management market. The Company offers a broad line of proprietary capital and consumable products including radiofrequency ablation generators, discography systems, cannulae, standard and specialty electrodes, grounding pads, epidural catheters, procedural tables and pharmaceutical compounding services to physicians trained in the field of interventional pain medicine. Over the past several years, the Company has expanded its product line and geographic reach through four different asset acquisitions bolstering the Company’s leading position in the interventional pain market. NeuroTherm is headquartered in Wilmington, Massachusetts with corporate offices in London, Amsterdam and Dusseldorf.
Cortec is a New York based private equity firm which invests in middle-market manufacturing, distribution, healthcare, and proprietary service businesses. Cortec acquires high value-added, middle-market specialty manufacturing, service, healthcare and distribution businesses with leadership positions in their market niches. Cortec Group Fund IV, L.P. has more than $410 million of committed capital to acquire platform companies with enterprise values of $30 million to $250 million and smaller follow-on acquisitions.
Located in the Cleveland suburb of Mayfield Heights, Ohio, Linsalata Capital Partners was founded in 1984 and has combined its strong financial capabilities with extensive operational experience to accelerate the growth of middle-market companies. In its more than 26 years of investing, the firm has completed 97 buy-side transactions totaling more than $3 billion. Linsalata Capital Partners is currently investing from its sixth fund, Linsalata Capital Partners Fund V, L.P. (LinCap V), with $425 million in committed equity capital.